ASX Lunch Wrap: ASX edges up on Wall Street’s record high, as Trump’s oil push stirs markets
News
News
The ASX ticked up in early trading on Friday, up by 0.35% following a rally on Wall Street overnight.
Wall Street hit record highs after Trump’s speech at the World Economic Forum in Davos, where he urged OPEC (Organization of the Petroleum Exporting Countries) to increase oil production in order to bring down prices.
Trump also suggested that if oil prices were reduced, it would accelerate the end of the Russia-Ukraine war.
The S&P 500 rose 0.5%, hitting a fresh all-time high, but oil stocks struggled after his comments.
On the ASX this morning, oil giants Woodside Energy Group (ASX:WDS) and Beach Energy (ASX:BPT) both dropped about 0.7%.
Consumer stocks, meanwhile, led the gainers, with Aussie retailers putting on a show. Both Wesfarmers (ASX:WES) and Harvey Norman Holdings (ASX:HVN) were up 3%.
Interest-rate sensitive real estate stocks also gained, largely on the back of Goodman Group (ASX:GMG)’s 1.5% jump.
In large caps news, IGO (ASX:IGO) announced that its joint venture partner Tianqi Lithium had decided to suspend the expansion of the Kwinana lithium refinery.
This decision has led to a reassessment of the project’s future, with IGO saying it will recognise a substantial impairment in its half-year results. IGO’s shares still rose 3%, with investors cheering its capital discipline as the first train continues to consume cash in a protracted ramp-up.
Here are the best performing ASX small cap stocks for January 24 [intraday]:
Security | Description | Last | % | Volume | MktCap |
---|---|---|---|---|---|
FHS | Freehill Mining Ltd. | 0.004 | 33% | 778,200 | $9,235,583 |
SFG | Seafarms Group Ltd | 0.002 | 33% | 5,529,919 | $7,254,899 |
AQN | Aquirianlimited | 0.240 | 33% | 452,123 | $14,535,715 |
CLU | Cluey Ltd | 0.050 | 32% | 460,171 | $13,407,302 |
IMI | Infinitymining | 0.013 | 30% | 441,476 | $4,210,158 |
AQD | Ausquest Limited | 0.031 | 29% | 52,876,001 | $27,118,433 |
CTQ | Careteq Limited | 0.014 | 27% | 155,033 | $2,608,306 |
14D | 1414 Degrees Limited | 0.030 | 25% | 116,905 | $6,780,030 |
BNL | Blue Star Helium Ltd | 0.005 | 25% | 95,811 | $10,779,541 |
GMN | Gold Mountain Ltd | 0.003 | 25% | 106,379 | $9,158,446 |
PRS | Prospech Limited | 0.026 | 24% | 101,956 | $6,905,344 |
AMD | Arrow Minerals | 0.054 | 23% | 4,770,815 | $29,091,953 |
SM1 | Synlait Milk Ltd | 0.440 | 22% | 447,763 | $217,151,315 |
AOK | Australian Oil. | 0.003 | 20% | 2,590,798 | $2,504,457 |
MRD | Mount Ridley Mines | 0.003 | 20% | 3,017,890 | $1,946,223 |
CND | Condor Energy Ltd | 0.032 | 19% | 5,834,282 | $15,831,009 |
CPO | Culpeominerals | 0.020 | 18% | 55,000 | $3,739,358 |
NRX | Noronex Limited | 0.014 | 17% | 943,307 | $5,996,249 |
RGL | Riversgold | 0.004 | 17% | 1,139,777 | $5,051,138 |
SPQ | Superior Resources | 0.007 | 17% | 70,409 | $13,019,183 |
Synlait Milk (ASX:SM1) skyrocketed 22% after the company bumped up its H2 guidance, and said it’s expecting a return to profitability this year, with an EBITDA forecast of $58-63 million.
Western Energetics (WE), the subsidiary of mining services company Aquirian (ASX:AQN), has just landed a juicy three-year, $20 million supply deal with Aurenne’s Mt Ida Goldmine in WA. The agreement will see WE deliver a tailored energetics and tech package, including its innovative Collar Keeper drill tech, helping to cut costs and boost efficiency.
Drilling is now underway at Noronex (ASX:NRX)’s Damara Copper Project in Namibia to test some high-potential targets in unexplored territory. Funded by South32 (ASX:S32) under an earn-in agreement, the project is set to explore the Kalahari Copper Belt’s gravity-magnetic bullseye features.
AusQuest (ASX:AQD) shares continue to climb after announcing the discovery of a copper-rich porphyry in Peru on Thursday. Read our interview with managing director Graeme Drew here.
Clarity Pharmaceuticals (ASX:CU6)’s shares jumped after US regulators fast-tracked its prostate cancer detection drug. The FDA’s decision will speed up the development process, allowing for quicker approval and more frequent communication during the development phase.
Here are the worst performing ASX small cap stocks for January 24 [intraday]:
Code | Name | Price | % Change | Volume | Market Cap |
---|---|---|---|---|---|
LNU | Linius Tech Limited | 0.001 | -33% | 206,666 | $9,226,824 |
VML | Vital Metals Limited | 0.002 | -33% | 226,184 | $17,685,201 |
H2G | Greenhy2 Limited | 0.003 | -25% | 55,000 | $2,392,737 |
ERA | Energy Resources | 0.002 | -20% | 2,398,274 | $1,013,490,602 |
PKO | Peako Limited | 0.004 | -20% | 125,000 | $5,475,708 |
RLG | Roolife Group Ltd | 0.004 | -20% | 150,000 | $5,980,156 |
TMK | TMK Energy Limited | 0.002 | -20% | 31,486,627 | $23,313,913 |
FNR | Far Northern Res | 0.125 | -19% | 38,581 | $5,621,203 |
GLA | Gladiator Resources | 0.009 | -18% | 5,340,093 | $8,341,265 |
HFY | Hubify Ltd | 0.009 | -18% | 1,557,069 | $5,622,499 |
S66 | Star Combo | 0.120 | -17% | 25,000 | $19,587,032 |
ASP | Aspermont Limited | 0.005 | -17% | 792,772 | $14,820,070 |
CRR | Critical Resources | 0.005 | -17% | 310,000 | $14,591,779 |
EE1 | Earths Energy Ltd | 0.010 | -17% | 2,570,901 | $6,359,571 |
KLI | Killiresources | 0.062 | -15% | 408,834 | $10,236,333 |
HYD | Hydrix Limited | 0.023 | -15% | 2,653,906 | $7,364,759 |
EUR | European Lithium Ltd | 0.059 | -14% | 2,655,988 | $99,717,521 |
ADN | Andromeda Metals Ltd | 0.006 | -14% | 485,971 | $24,001,094 |
IPB | IPB Petroleum Ltd | 0.006 | -14% | 7,843 | $4,944,821 |
MKL | Mighty Kingdom Ltd | 0.006 | -14% | 1,111,112 | $1,512,444 |
ROG | Red Sky Energy. | 0.006 | -14% | 1,428,907 | $37,955,590 |
VFX | Visionflex Group Ltd | 0.003 | -14% | 28,916 | $11,787,512 |
Kogan (ASX:KGN) crashed by 14% despite reporting solid revenue growth of 9.9% for the first half of FY25. The retailer’s gross sales rose by 10.3%, but investors weren’t too thrilled with its outlook, showing wider worries about the sector.
Drug developer Paradigm Biopharmaceuticals (ASX:PAR) has received $6.3m from a R&D tax incentive refund for last financial year – bringing the company’s current cash balance to roughly $31m.
PAR’s cash on hand means the company is well positioned to continue its current Phase 3 clinical trial for an injectable therapy to treat osteoarthritis.
At Stockhead, we tell it like it is. While Paradigm Biopharmaceuticals is a Stockhead advertiser, it did not sponsor this article.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.